Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Osteoporosis treatment].

Brigitte Uebelhart1, René Rizzoli

  • 1Service des maladies osseuses, Centre collaborateur de l'OMS pour la prévention de l'ostéoporose, Département de réhabilitation et gériatrie, HUG, Genève. Brigitte.Uebelhart@hcuge.ch

Revue Medicale Suisse
|March 16, 2007
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Preventing post-denosumab bone loss with zoledronate: a 2-year randomized trial in post-menopausal women without and with pre-exposure to bisphosphonates.

Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA·2026
Same author

Publisher Correction: Probiotic Supplementation and Bone Health Parameters in Adults: A Systematic Review and Meta-Analysis.

Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA·2026
Same author

Health-related quality of life instruments for older persons with osteoporosis: a WHO-BOHEG systematic review of measurement properties for use in clinical trials and routine practice.

Age and ageing·2026
Same author

Albumin-adjusted ("corrected") calcium should no longer be reported: a position statement from the Joint IOF Working Group and IFCC Committee on Bone Metabolism and EFLM Committee on CKD.

Clinical chemistry and laboratory medicine·2026
Same author

Expert consensus on hyaluronic acid injections for knee osteoarthritis: a patient-centered approach.

Aging clinical and experimental research·2026
Same author

"Build better bones": development, launch, and future directions of a multilingual, user-centered website for osteoporosis management.

Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA·2026
Same journal

Revue medicale suisse·2026
Same journal

Revue medicale suisse·2026
Same journal

Revue medicale suisse·2026
Same journal

Revue medicale suisse·2026
Same journal

Revue medicale suisse·2026
Same journal

[Erythema multiforme : target deciphering].

Revue medicale suisse·2026
See all related articles

Osteoporosis diagnosis uses bone density, while treatment considers risk factors. Several medications like Denosumab, Tibolone, Strontium ranelate, parathormone, and bisphosphonates effectively reduce fracture incidence.

Area of Science:

  • Endocrinology and Bone Metabolism
  • Pharmacology of Osteoporosis Therapeutics

Context:

  • Osteoporosis diagnosis relies on bone mineral density thresholds.
  • Therapeutic strategies are influenced by individual clinical risk factors.

Purpose:

  • To review current therapeutic options for osteoporosis.
  • To highlight the efficacy and specific applications of various bone resorption inhibitors.

Summary:

  • Denosumab, a RANK-Ligand inhibitor, effectively reduces fracture incidence when combined with calcium and vitamin D.
  • Tibolone and Strontium ranelate offer vertebral fracture prevention, though Tibolone carries a stroke risk.
  • Parathormone (84AA) and bisphosphonates (Alendronate, Ibandronate, Zoledronate) represent diverse treatment modalities, with yearly zoledronate injections showing broad fracture prevention.

Related Experiment Videos

Impact:

  • Provides a comprehensive overview of osteoporosis treatment options.
  • Informs clinical decision-making for managing osteoporosis and preventing fractures.
  • Highlights the evolving landscape of bone antiresorptive therapies.